Designed Vehicles for Blood Brain Barrier Traversal
设计用于穿越血脑屏障的车辆
基本信息
- 批准号:10614470
- 负责人:
- 金额:$ 49.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-15 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAlzheimer&aposs DiseaseAminesAntibodiesBindingBinding ProteinsBiodistributionBiological AssayBloodBlood - brain barrier anatomyBrainCellsCentral Nervous SystemClinicalClinical TrialsDNA biosynthesisDiffusionDirected Molecular EvolutionDrug Delivery SystemsEscherichia coliFeedbackFutureGene PoolGoalsHydrogen BondingHydrophobicityIn VitroKnowledgeLabelLibrariesMeasuresMediatingMissionModelingMolecular Sieve ChromatographyMonoclonal AntibodiesMusNeurodegenerative DisordersNeurologicNeurological outcomeNucleocapsidNutrientOncogenesOutcomeParkinson DiseasePeptidesPermeabilityPharmaceutical PreparationsPharmacologyPropertyProtein EngineeringProteinsPublic HealthRadiolabeledRodentRouteSideSignal TransductionSpecificityStrokeStructureSurfaceSynthetic GenesSystemTFRC geneTherapeuticTherapeutic Monoclonal AntibodiesToxic effectUnited States National Institutes of HealthVariantVertebral columnX-Ray CrystallographyYeastsbarrier to careblood-brain barrier crossingblood-brain barrier penetrationblood-brain barrier permeabilizationbrain cellchemical propertychemical synthesisdelivery vehicledesigndesign,build,testdisabilityimprovedimproved outcomein vivoinnovationinsightnervous system disordernovel drug classnucleic acid-based therapeuticspassive transportreceptorreceptor bindingscreeningsuccesstool
项目摘要
PROJECT SUMMARY
Emerging peptide-, protein-, and nucleic acid-based therapeutics for the treatment of Alzheimer’s disease and
other neurologic conditions are blocked from diffusing into the brain by the blood–brain barrier (BBB). The
long-term goal of this project is to deliver large therapeutic cargo such as these into the brain using designed
BBB-crossing drug-delivery vehicles. The overall objectives are to (i) leverage recent breakthroughs in
computational peptide design to yield new knowledge about BBB permeability and (ii) to designed from scratch
new proteins that ferry cargo into the brain by exploiting natural systems that the brain uses to receive nutrients
and signals. The central hypothesis is that the systematic design of functional biomolecules will yield new
insights and tools for improving the delivery of large biomolecule therapeutics into the brain. The specific aims
are: 1) to systematically and rationally discover the physiochemical properties which confer BBB permeability
to designed peptide macrocycles (a promising new class of therapeutics); 2) to computationally design small,
hyperstable proteins which bind to receptors that naturally cycle between the blood- and brain-side of the BBB;
and 3) to fuse the binding proteins generated in Aim 2 to various drug-binding/packaging proteins, thereby
creating protein assemblies that ferry large therapeutics into the brain. This project is innovative because it
proposes to resolve a long-standing barrier to the treatment of neurologic diseases (namely, the difficulty of
delivering therapeutics into the brain) by designing from scratch new BBB-crossing drug delivery vehicles. The
project is significant because it is expected to provide tools which will improve outcomes in a range of future
clinical trials of therapeutics which require delivery into the brain.
项目概要
用于治疗阿尔茨海默病和基于肽、蛋白质和核酸的新兴疗法
血脑屏障(BBB)阻止其他神经系统疾病扩散到大脑。
该项目的长期目标是使用设计的方法将诸如此类的大量治疗货物输送到大脑中
跨越 BBB 的药物输送工具的总体目标是 (i) 利用近期的突破。
计算肽设计,以产生有关 BBB 渗透性的新知识,以及 (ii) 从头开始设计
新蛋白质通过利用大脑用来接收营养的自然系统将货物运送到大脑中
和信号的中心假设是功能生物分子的系统设计将产生新的结果。
改善大生物分子疗法向大脑输送的见解和工具具体目标。
1)系统合理地发现赋予BBB通透性的理化性质
设计肽大环化合物(一种有前途的新型疗法);2)通过计算设计小的、
超稳定蛋白质,与 BBB 的血液侧和大脑侧之间自然循环的受体结合;
3)将目标2中产生的结合蛋白与各种药物结合/包装蛋白融合,从而
创建将大量治疗药物输送到大脑中的蛋白质组装体,因为它是创新的。
提出解决神经系统疾病治疗的长期障碍(即治疗困难)
通过从头开始设计新的穿过血脑屏障的药物输送载体,将治疗药物输送到大脑中。
该项目意义重大,因为预计它将提供能够改善未来一系列结果的工具
需要输送到大脑的疗法的临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID BAKER其他文献
DAVID BAKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID BAKER', 18)}}的其他基金
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
针对 COVID-19 和未来大流行病的 Minibinder 拮抗剂的从头设计
- 批准号:
10460648 - 财政年份:2021
- 资助金额:
$ 49.55万 - 项目类别:
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
针对 COVID-19 和未来大流行病的 Minibinder 拮抗剂的从头设计
- 批准号:
10296596 - 财政年份:2021
- 资助金额:
$ 49.55万 - 项目类别:
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
针对 COVID-19 和未来大流行病的 Minibinder 拮抗剂的从头设计
- 批准号:
10672446 - 财政年份:2021
- 资助金额:
$ 49.55万 - 项目类别:
Project 4: Novel reagent development to enable molecular characterization
项目 4:开发新型试剂以实现分子表征
- 批准号:
10359195 - 财政年份:2020
- 资助金额:
$ 49.55万 - 项目类别:
Project 4: Novel reagent development to enable molecular characterization
项目 4:开发新型试剂以实现分子表征
- 批准号:
10573273 - 财政年份:2020
- 资助金额:
$ 49.55万 - 项目类别:
Designed Vehicles for Blood Brain Barrier Traversal
设计用于穿越血脑屏障的车辆
- 批准号:
10400878 - 财政年份:2019
- 资助金额:
$ 49.55万 - 项目类别:
Designed Vehicles for Blood Brain Barrier Traversal
设计用于穿越血脑屏障的车辆
- 批准号:
10200639 - 财政年份:2019
- 资助金额:
$ 49.55万 - 项目类别:
Design of de novo interleukin mimics for targeted immunotherapy
用于靶向免疫治疗的从头白细胞介素模拟物的设计
- 批准号:
9796930 - 财政年份:2019
- 资助金额:
$ 49.55万 - 项目类别:
Design of de novo interleukin mimics for targeted immunotherapy
用于靶向免疫治疗的从头白细胞介素模拟物的设计
- 批准号:
10475003 - 财政年份:2019
- 资助金额:
$ 49.55万 - 项目类别:
Designed Vehicles for Blood Brain Barrier Traversal
设计用于穿越血脑屏障的车辆
- 批准号:
9796948 - 财政年份:2019
- 资助金额:
$ 49.55万 - 项目类别:
相似国自然基金
基于神经退行性疾病前瞻性队列的新烟碱类杀虫剂暴露对阿尔茨海默病的影响及作用机制研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
基于miRNA介导ceRNA网络调控作用的防治阿尔茨海默病及认知障碍相关疾病药物的发现研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
LMTK1调控核内体转运介导阿尔茨海默病神经元Reserve机制研究
- 批准号:81903703
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
基于自组装多肽纳米探针检测蛋白标志物用于阿尔茨海默病精准诊断的研究
- 批准号:31900984
- 批准年份:2019
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
靶向干预CD33/Aβ相互作用改善小胶质细胞功能延缓AD病理进程
- 批准号:81901072
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 49.55万 - 项目类别:
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
- 批准号:
10678341 - 财政年份:2023
- 资助金额:
$ 49.55万 - 项目类别:
Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
开发用于常规生成正交 GPCR 靶向纳米抗体的集成管道
- 批准号:
10603669 - 财政年份:2023
- 资助金额:
$ 49.55万 - 项目类别:
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
阿尔茨海默病和唐氏综合症中 APP 拷贝数变异对 Reelin 表达和功能的影响
- 批准号:
10760161 - 财政年份:2023
- 资助金额:
$ 49.55万 - 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
- 批准号:
10660332 - 财政年份:2023
- 资助金额:
$ 49.55万 - 项目类别: